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Abstract: 
PDT is an emerging cancer treatment that combines both light and a photosensitizing agent 
to produce reactive oxygen in cells. Although upconversion nanoparticles (UCNPs) are attracting 
much attention for their potential biological application, there are still several drawbacks that limit 
its general clinical use such as limited tissue penetration depth and sever overheating effect. 
Consequently, there has been extensive nanoparticle surface modification research into the design 
of improved alternative photosensitizers aimed at overcoming these drawbacks. Therefore, the 
goal of this project was to enhance the surface modification of UCNP to demonstrate high 
upconversion luminescence efficiency, as well as have hydrophilic surface characteristics that are 
compatible with biomolecule. Thus, based on recommendations from the previous MQP research 
group, team conduct repeating experiments in alternative UCNPs with different laser power 
density (we used 800nm whereas the previous MQP used 980nm) and address the possible over 
heating concerns through in vitro tests by enhancing tissue penetration depth and optimize singlet 
oxygen production to kill cancer cell.  
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Chapter 1: Introduction  
Cancer is the fifth leading cause of death in the United States. In 2014, approximately 
1,665,000 new cancer cases and 585,000 cancer deaths are projected to occur in the U.S. alone 
(Siegel, 2014). Several treatment options include radiotherapy, chemotherapy, and surgery. These 
treatments subject the patient to harmful side effects due to the damage of healthy cells and may 
lead to another cancer in later life. Photodynamic therapy (PDT) has been investigated as a 
technique that combines light energy and drug therapy to actively target and monitor diseased 
tissue. PDT can consider as medical miniature tools by combining a systematic administration of 
a nontoxic photosensitizing (PS) drugs along with light to kill cancer cells. Over a certain amount 
of time the drug selectively accumulated in the cancer cells, then applying specific wavelength of 
light causes the drug to react with oxygen destroy the tumor cell. Since PS alone is nontoxic and 
ineffective so typical PDT treatments involve three components: the photosensitizer, oxygen and 
light source within the tissue (Zhang, 2014).  
 Lanthanide doped upconversion nanoparticles (UCNPs) are the luminescent trivalent ions 
which are able to convert low energy light to high energy light. These particles can be used in PDT 
to replace or to assist traditional organic dyes and ultra violet (UV) phosphors, because they are 
optically active to produce emission when excited. UCNPs-PDT is well suited for use in 
theranostics that can consequently increase patient survival, since it has a unique form of 
nonionizing radiation therapy that administered via light-absorbing substance, and has zero 
autofluorescence background to adjust the signal-to-noise ratio. In addition, UCNP’s have great 
potential to contribute to deeper tissue penetration of nanoparticle excitation wavelengths and 
increased emission intensity and reduced light scattering, because UCNPs are nonbinding, and less 
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light scattering. Thus, lanthanide-doped UCNPs have attracted our attention to work on a team of 
students, academic advisor from WPI, and physician from UMASS Medical School to design and 
test UCNPs for PDT to maximize light penetration through biological tissue.  
 Lanthanide UCNPs refers to an anti-stokes type process that convert sequential absorption 
of NIR light to visible/UV light. Dr. Han’s lab has patented a variety of novel nanoparticles for 
PDT with excitation peaks at both 800nm and 980nm. Because these particles must be synthesized 
in organic solvents, their surfaces contain toxic ligands that limit their use in cell therapy and drug 
delivery. Through functional group conjugation, we are able to replace toxic ligands with a 
hydrophilic coating that is coupled to 5-amino levulinic acid (5-ALA). 5-ALA is a precursor in the 
biosynthesis of protoporphyrin IX (PpIX) which is a photo excitable porphyrin with an excitation 
peak of 470nm. By delivering exogenous 5-ALA to cancer cells in vitro, the Han lab has 
demonstrated the ability to stimulate PpIX production and finally leads to formation of heme. After 
PpIX accumulates in the cell, the UCNP can be excited and converts the 800nm NIR light to a 
470nm wavelength UV emission, which then activates PpIX. A red light emission at 670nm from 
the PpIX molecule is then responsible for the inducing a higher energy state to cellular triplet 
oxygen, which catalyzes the formation of singlet oxygen or reactive oxygen species (ROS). This 
excited state of the oxygen molecule then begins to denature cellular proteins and results in cell 
death. 
Clinical applications of UCNP’s have been limited due to the negative heating effects of 
high-powered lasers and the limited tissue penetration of low-powered lasers. Our work aims to 
investigate the heating effects and tissue penetration depth of the 800nm laser in comparison to 
the 980nm laser at FDA regulated 0.7 Watts/cm2 power density for effective biological use. As a 
10 
 
 
number of studies have focused on tuning upconversion emission using core @shell architectures 
with two or more Ln3+ activators are best solution to regulate heating effects and apply for 
biological application. One major limitation of conventional UCNPs is the low conversion 
efficiency especially under a low-intensity laser excitation due to extremely weak absorption of 
sensitizer Yb3+ ion as well as having very narrow NIR absorption spectral window that cause 
serious overheating damage (Zhang, 2014). Therefore, we aimed to enhance the surface 
modifications of our particle by investigating alternative conjugation and/or drug delivery 
vehicles. We hypothesized that surface modifications of ALA can improve its cellular 
permeability, increased stability in physiologic pH and increased selectivity and limitation of side 
effects. The current process of hydrazine coating and ALA conjugation decreases luminescent 
intensity and increases particle size. Increased size makes targeted cellular uptake more 
challenging because smaller particles permeate cell membranes more easily. We tested the 
effectiveness of our UCNP delivery in vitro using HELA cells and an MTT assay to determine the 
effectiveness of our particle to cells. Pork tissue was used to test the heating effects of the 800nm 
laser compared to the 980nm laser.   
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Chapter 2: Background 
Unlike normal cell growth and death, cancer cells continue to grow and form new abnormal 
cells that invade or grow into other tissues. In the cancer cells the damage DNA is neither repaired 
nor causes cell death like it should, therefore, the cell goes on making new cells. Cancer has many 
possible causes and ability to travel to other parts even get into the body’s bloodstream or lymph 
vessels of the body where they can grow and form new tumors spreading is called metastasis. 
Although not all tumors are cancer (Unlike malignant tumors, benign tumors are not cancerous 
and they don’t spread to the other part of the body), different types of cancer can behave very 
different rate and respond to different treatments. That is why people with cancer needs special 
attention and treatment to cure their kind of cancer.  
Cancer is a 2nd most prevalent cause of death for all ages and, in 2010 was the leading cause 
of death for the people ages 40 – 79. According to Siegel, et al, in 2014 there were 1.6 million new 
cases of cancer and 580,000 deaths in United States (U.S.), which figures out to 1600 deaths per 
day (Siegel, 2014).. These risk estimates the lifetime risk of developing and dying from cancer that 
measure of how widespread cancer is in the U.S.  
Cancer treatment is challenging because it is difficult to remove cancerous tissues without 
damaging healthy cells. There are various types of cancer treatments such as: chemotherapy, 
radiation therapy, or surgery. In chemotherapy, various chemicals are used to kill the targeted 
cancer cells using anti-cancer drugs, when injected into vein/bloodstream the drug travels to reach 
and destroy the cancer cells. In radiation therapy, high-energy radiation is used to kill the cancer 
cells by damaging their DNA. There are multiple transplantation surgeries used to help treat 
patients such as: bone marrow transplantation, peripheral blood stem cell transplantation and 
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childhood hematopoietic cell transplantation. However, because it uses high energy X-ray or 
particles to kill cancer cells and cancers don’t usually have discrete tumors size or behavior, it is 
difficult to avoid side effects that include nausea, fatigue, and hair loss, vomiting, diarrhea, and 
loss of appetite when the radiation enters the body.   
There are a lot of other side effects of chemotherapy and radiation such as: dental problems, 
fatigue, diabetes, endocrine problems, hypothyroidism, incontinence, infertility, memory 
problems, learning disabilities, lymphedema, neuropathy, organ damage, osteoporosis, general 
pain, premature aging effects, and sexual problems (MD Anderson Cancer Center, 2014). 
There is another treatment for cancer which is known as Photodynamic Therapy (PDT) on 
which our project focused on. PDT is considered to be minimally invasive when compared with 
chemotherapy and radiotherapy because it allows for better detection and eradication of diseased 
tissue without harming healthy cells (Dai et al., 2012) since it uses special photosensitizer agents 
that act as drugs along with certain kind of light to kill cancer cells. Unlike radiotherapy, PDT is a 
form of nonionizing radiation therapy and it can be repeated many times at the same site with only 
short time of treatment. However; there are some limitation to this treatment as well such as it can 
only treat cancer up to 12mm of tissue depth and has higher heating effects which causes skin 
burning.  
2.1. Photodynamic Therapy in Medicine 
Photodynamic therapy (PDT) is a treatment that uses a drug called a photosensitizing agent 
or photosensitizer along with a particular light energy, which can target cancer cells and kill them 
(American Cancer Society, 2013). Photodynamic therapy has significant advantages compared to 
current treatments because it has no long-term side effects if use properly (Dai et al., 2012). It is 
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less invasive than surgery, it is easy to use, it can be targeted very precisely and it often costs less 
than many cancer treatments. Depending on the treatment area the photosensitizing agents are 
injected interstitially, intravenously, inhaled, or topically applied. Once the upconversion 
nanoparticle are injected, they can take 24-72 drug-to-interval hours (which is period of time 
between the drug given time to the light is applied) as shown in figure 1. 
 
Figure 1: General Schematic of PDT mechanism 
The use of NIR light excitation, and utilizes photo triggered chemical drugs 
(photosensitizes) to produce singlet oxygen (1O2) to kill tumors. The successful PDT incorporates 
three main components that includes the photosensitizer, the light source, and the oxygen within 
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the tissue at the diseases site, killing the tumor cells. Photosensitizer is injected to cancer patient 
and NIR light is shine on it which covert ordinary oxygen to aggressive toxic singlet oxygen. 
Singlet oxygen is extremely toxic to cells but it is so reactive to that it burn itself almost insistently 
and only damage near spots where it was generated which is why this treatment is has less 
damaging to healthy tissues.  
Even though PDT has shown great potential, it still has limitations as well. The main 
limitations for this application are tissue penetration depth of 1 millimeter which can only treat 
skin surface cancer due to lack of PpIX accumulation that reduce damage of deeper layers. There 
are some side effects to this treatment as well, such as severe toxicity kills the healthy tissues 
around tumor cells. Patients are also advised to not go under bright light for at least a week. 
Although there are some limitations to this treatment, it still has advantages over treatments such 
as chemotherapy, radiology, and surgery, which are expensive and not ideal for every cancer 
disease. 
2.2. Nanoparticles in Medicine 
As Chen et al. defined how to develop high-quality lanthanide-doped luminescent 
nanoparticles with adjustable crystalline phase, shape, and size is crucial for variety of potential 
medical applications such as drug delivery for cancer treatment and molecular imaging (Chen, 
2014). Upconversion nanonparticle (UCNPs) have emerged recently as a type of nanoparticles. 
They are combination of doped-lanthanide elements. Continuous absorption of multiple photons 
on the lanthanide ions assist for effective energy transfer to facilitate photochemical reactions that 
help for advance drug delivery. They can absorb near infrared light (NIR) and convert this low 
energy light into high energy light and emit ultra violet light (UV) visible light. The mechanism 
15 
 
 
of the energy transfers within lanthanide UCNPs process is an important process for PDT since 
photosensitizer alone is nontoxic and ineffective.  
There are various nanochemistry research to produce upconversion nanoparticles (UCNPs) 
in highly control manner such as hierarchical core/shell UCNPs, thermolysis strategy, Ostwald-
ripening method, and hydro (solvo) thermal strategy. Our project focuses on the novel method of 
the core/shell UCNPs that can control the composition of phase and size. It is believed that the 
diameter of nanoparticles for cancer therapeutics should be in the range of 10 – 100 nm 
(Commission, E., 2006)). The nanoparticles should be accessible to and disseminated within 
tumors in order to be effective to kill tumors. It is possible to inject particles directly into tumors. 
However, particles may still be forced from cancerous tissue and enter circulation where they tend 
to accumulate in the liver (Duncan et al., 2010).  
As PDT there is another application of nanoparticles in medical research for early cancer 
detection, screening, and use for therapeutic purposes for life-threatening diseases called 
Photoluminescence imaging (PL). High contrast cellar imaging using the engineered UCNPs can 
increase the saturation threshold to accomplish cell imaging with both high resolution and high 
contrast. The optical/magnetic nanoparticles application key factor in biomedical imaging is the 
particle size. For this application, the emission intensity and size of the nanoparticle are mutually 
dependent parameters, and in general, weak emission resulted from a smaller nanoparticle size 
(Wang, 2013). Wang et al. indicated that the surface modification of nanoparticles enable the 
cellular uptake efficiency more that could be used to image variety of cell lines through cellular 
endocytosis way in HELA cells (Wang, 2013). Hence, nanoparticles can be characterized by size, 
shape, and chemical composition. 
16 
 
 
 The surface volume ratio of nanoparticles increase by reducing the size of the 
nanoparticle. Reduced size has been shown most effective for use in drug delivery (Wang, 2013). 
The chemical composition of the nanoparticle is also important and can affect the toxicity and 
cellular targeting. The reactivity of nanoparticles can be affected by the chemical absorption on 
the surface of nanoparticle. Shape is another factor that has to be considered to reduce the toxicity 
and enhance targeting. For example, nanotubes a few nanometers in diameter but with several 
micrometers length can leave the carcinogenic effects. Thus, the nanochemistry for controlled 
synthesis helps for PL imaging to demonstrate various animal imaging, testing the biocompatibility 
behavior of UCNPs as well as for theranostic applications.  
Depending on the part of the body being treated or people with certain types of cancer, the 
photosensitizer agent is directly injected into the bloodstream of the vein and light is applied to the 
area that needs to be treated. This light cause the reaction to kill cancer cells. This is known as 
PDT and it can be used in people with certain types of cancer to help them live longer and improve 
their quality of life. Although several photosensitizing agents are currently approved by the US 
Food and Drug Administration (FDA) to treat cancers and studies have shown that PDT can work 
better than surgery or radiation therapy, however; it has few limitations. As American Cancer 
Society specified, the main limitation is, it can’t be used to treat malignant cancers, special 
precautions must be taken after the drugs are put in, because it can lead swelling and other possible 
side effects.  
2.3 UCNP Structure 
UCNP-based therapeutic applications have shown promising results in drug delivery and 
PDT through increasing the lipophilicity. The advantage of modification ALA-PDT improve 
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cellular permeability, increased stability pH concentration, increased selectivity of UCNP-
photosensitizer into tumor, and enhance the rate of their enzymatic conversion into photoactive 
compounds (Malgorzata et al. 2013) Similarly, the Han lab has developed a novel class of cascade 
sensitized, lanthnide-doped, core-shell, 980nm excitation wavelength UCNPs for use in PDT, 
however; they had limitation of deep tissue penetration and higher heating effects. Then Han lab 
developed a novel class of cascade sensitized, lanthnide-doped, core-shell-shell, 800nm excitation 
wavelength USNPs for use in PDT. These particles use neodymium (Nd) as a photonnsensitizer, 
ytterbium (Yb) as a bridging ion, and thulium (Tm) as an activating ion. Fusing these lanthanide 
ions within a dielectric lattice, the Han lab has been able to tailor the emission wavelength of their 
novel UCNPs to overlap the absorption spectra of naturally occurring photosensitizer PpIX. This 
allows for luminescence upon laser excitation as well as activation of radical oxygen species 
(ROS) within cells. Changing the concentration a neodymium allows for emission wavelength 
tunability. Dr. Han’s lab has studied the luminescent efficiency of various neodymium 
concentrations in order to optimize luminescent intensity that overlaps the emission spectra of 
PpIX (Shen et al., 2013). By delivering nanoparticles directly to the cancerous cells, the localized 
UV emission necessary to activate PpIX and catalyze singlet oxygen production can be induced 
noninvasively using a cheap NIR laser, which has minimal heating effects and damage to 
surrounding healthy tissue. The optimal transparency window for biological tissue penetration is 
spectral range of 750 – 1000 nm (Yang et al., 2014). After conducting research the team decided 
to experiment 800nm UCNPs.  
2.4 Function 
In order to accomplish effective drug delivery and enhance photodynamic therapy, the 
particle must be multifunctional. The specific functions of a successful product include intense 
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luminescence, targeted delivery, and significant PpIX and ROS production. Luminescence 
intensity is engineered by changing ion and ligand concentrations in a homogenous or 
heterogeneous core/shell/shell structure. We aim to utilize a heterogeneous UCNP core and 
fluoride based dielectric lattice. Surface engineering is necessary to remove toxic ligands and 
incorporate biocompatible targeting mechanisms in order to enhance drug delivery. ALA is a 
precursor to PpIX and has been shown to stimulate PpIX production, particularly in cancer cells. 
By increasing conjugation density of ALA to the surface of our particles, we are able to enhance 
PpIX production, resulting in intense luminescence and increased ROS production (Chen et al., 
2014). 
It has been shown that cancer cells express a variety of unique signaling mechanisms. The 
ALA uptake mechanisms of various cancer cells have been studied using ALA derivatives and 
esters (Rodriguez et al., 2006). ALA is taken up by Beta transport mechanisms such as Gat-2 and 
Gat-3 (Rodriguez et al., 2006). Different modifications to the ALA molecule result in different 
uptake mechanisms (Rodriguez et al., 2006). 
2.4.1 Polymer Chemistry/Ligand Exchange 
Lanthanide based UCNP’s are hydrophobic and can dissolve in the nonpolar solvents but 
not in biological buffer or aqueous solution, which limits their applications for PDT (Wang, Cheng, 
& Liu, 2013). It is necessary to change the surface of UCNP’s from hydrophobic to hydrophilic, 
making them more water-soluble so they can be used in bio-analytical applications. The surface 
of the nanoparticles can be modified using a ligand exchange method. In this method the 
replacement of hydrophobic ligands occurs with hydrophilic ligand without significantly affecting 
the chemical and optical properties of UCNPs (Chen et al., 2014). After becoming hydrophilic, the 
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polymers become more stable, avoiding aggregation and precipitation during application. One way 
to make the nanoparticle hydrophilic is the conjugation of hydrazine. Hydrazine is hydrophilic, 
inorganic compound, stable in solution and carries a positive charge. 
2.4.2 Protoporphyrin IX (PPIX) 
Protoporphyrin IX (PpIX) is produced in cells via the heme synthesis pathway from the 
substrate of ALA. In addition to being able to target the UCNPs ferrochelatase converts the PpIX 
into heme. Ferrochelatase is typically overexpressed in cancer cells. The heme synthesis pathway 
is usually under tight control with feedback inhibition by heme controlling the synthesis of ALA. 
PpIX is commonly used for photodynamic therapy, and for tumor detection because it can emit 
light energy to produce singlet oxygen, which kills the cancer cells. PpIX is known to be an 
excellent photosensitizer because of its minimal photo-damage effects. ALA is an FDA approved 
photosensitizer and ALA-derived PpIX methods have been clinically used in PDT. 
After conducting the research we decide to use 800nm excitation laser which emits blue 
light and has shorter wavelength and higher frequency. The purpose of using blue light is that it 
has is brighter emission and produce more PpIX than red light which will kill more cancer cells.  
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Chapter 3: Objectives  
In this chapter we will discuss our goals for this project and how we plan to target each 
element. Last year MQP team were able to made a core-shell UCNPs particle to make PDT better. 
The goal of their project was to use red visible light using 980nm laser to activate ALA to produce 
singlet oxygen. There particle enhanced light penetration of 1.2cm in pork tissue and was great to 
use in photodynamic therapy. However; they had limitation of higher heating effects, less 
emission. After conducting research on PDT, UCNPs and pervious MQP we discovered that there 
is need for enhanced treatment for PDT using UCNPs. Thus, our goal was to investigate 800nm 
laser which has brighter emission and investigate heating effects of 800nm and 980nm LED lasers 
at the clinically approved power density of 0.7 watt/cm2 has less heating effects.  
3.1 Initial Client Statement 
Following is the initial statement was provided by our client.  
“Investigate coating mechanisms that will increase the solubility and tissue penetration 
depth of hydrophobic UCNP’s while maintaining high upconversion (UC) efficiency and 
minimizing surface related deactivations in order to utilize UCNP’s for photodynamic 
therapy (PDT). Specifically, to kill HeLa cells, in vitro, using a visible or wavelength 
UCNP core and photosensitizer doped shell structure which absorbs emitted photon 
energy to activate the formation of reactive oxygen species (ROS) in surrounding cells 
resulting in apoptosis.” 
 Afterward more research was conducted on PDT and UCNPs as well as meetings were 
arranged with clients to better understand the need and expectation from our client.  
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3.2 Objectives 
 After conducting research team discovered a lot of information regarding UCNPs and 
PDT which then was used to lay out the objectives of in a list based on current limitation with 
980nm UCNPs. After analyzing the client statement and researching UCNPs objectives were 
made as shown below.  
 Brighter blue light 
o More than 5*107 A.U   
o Brighter emission than red light  
 Particle size  
o Diameter between 30-50nm 
o After conjugation diameter between 35- 70nm 
 Safety and biocompatibility  
o Cellular survival rate before radiation treatment  
o Reduce laser heating effects 800nm vs. 980nm  
 Enhanced MTT assay  
o Cell viability of >50% 
After organizing the list of objectives they were broken down into detail objectives. We 
wanted our blue light to be produce brighter emission >5*107 A.U because brighter emission will 
have higher wavelength. Diameter of UCNPs particle size should be under 30-50nm and after 
conjugation it should be between 35-70nm because as research shows cancer cells can uptake those 
cells easily. Have less heating effects than 980nm using FDA approved density for patient safety. 
Finally, cell killing above 50% which will prove our project is success. 
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3.3 Final Client Statement 
After having meetings with client we came up with this final client statement as shown below.    
“Investigate the heating effects of the 800 and 980nm LED lasers used to activate 
lanthanide doped UCNP’s for photodynamic therapy (PDT). Specifically, study the cell 
viability and free radical production of HeLa cells, in vitro, using NIR-to-UV UCNPs 
which activate PpIX to catalyze the formation of reactive oxygen species (ROS) in 
surrounding cells resulting in cell death.”  
3.4 Project Strategy  
After final client statement our project goals were clear since we had limited budget we 
prioritized biocompatibility as an important goal. Our project will utilize blue light emission 
(470nm) from the UCNP to activate the photosensitizer PpIX; thus, the system must efficiently 
produce a bright, effective blue light in the presence of PpIX. Bodily tissue has an optimal 
transparency window of 700 – 1100 nm. Since 470nm does not fall within the optimal transparency 
window we must use a UCNP that enables the deeper penetrating 800nm or 980nm light to be 
converted to the 470nm wavelength necessary to activate PpIX, which catalyzes oxygen radicals. 
The stability of the UCNP system will be considered with respect to consistent hydrazine coating 
and ALA conjugation density, which also contribute to cell uptake and ROS production. To check 
the size and consistency of UCNPs Transmission electron microscopy (TEM) will conducted and 
to check the cell viability team will conduct MTT assay test. Finally, the 800nm excitation is 
hypothesized to reduce the heating effects on surrounding tissue compared to the 980 nm 
excitation wavelengths for which laser heating effects will be experimented. 
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Chapter 4: Alternative Design  
4.1 Requirement Analysis:  
The ability to fine tune UCNP material properties is what makes them an attractive area of 
research for photodynamic therapy. The ability to alter nanoparticle chemical and optical 
properties is vast but is also limited. Certain design changes can have negative side effects and 
research is necessary to determine the dependence between variables like size, shape, optical 
properties, and toxicity. We are focusing on the laser heating side effects and particle toxicity and 
their dependence upon size and optical properties. We are then concerned with optical properties 
and their dependence on particle composition and lattice structure. Particle composition is again, 
a vast area of interest but our research is limited to a select combination of lanthanide doped 
UCNPs. The structure is dependent upon the material used which is limited to a dielectric fluoride 
host lattice. 
As mentioned in earlier chapter, it is proven by previous MQP group that 980nm excited 
UCNP can be used for PDT but they have few limitations. The major limitation of the most 
commonly used Yb3+ -sensitized UCNPs are physically fixed excitation band at 980 nm that cause 
maximum absorption peak of water molecules and increase the heating effects. The purpose of our 
project was to come up with the 800nm UCNP which can decrease the heating effect and enhanced 
the cell viability. In order to make 800nm UCNP effective for PDT by overcoming the limitations, 
it was necessary for the team to do research that how 800nm UCNP can be conjugated to enhance 
the brightness of the particle, lowering heating effects and enhancing cell viability.  
There are a variety of molecules within the human body that are sensitive to light and the 
UV photons can manipulate the functions of biomolecules for onsite drug release via effective 
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photo activation. The pro-drug stimulation and photo-excitation of PpIX at 470nm has been FDA 
approved for the treatment of pre-cancerous lesions of the face and neck. Research into using up-
conversion nanoparticles as transducers to convert the deep tissue penetrating NIR light to UV 
photocatalyst is necessary to determine if this photodynamic therapy is effective in terms of 
possible negative heating effects of the laser along with nanoparticle toxicity to cells. Even though 
NIR-UCNPs has vital role for the biomedical research with excellent light penetration depth, it 
requires that precise light control and sufficient energy activated photosensitizer can lose its energy 
by emitting fluorescence as well as generate 1O
2.  
Molecules within human tissue absorb, reflect, and trap light energy causing it to be 
reflected or scattered at the skin surface which can be used for photodynamic therapy. In order to 
enhance the effectiveness of this mechanism we must better understand the optimal wavelength 
for tissue penetration with limited side effects such as unwanted heat, pain, or collateral tissue 
damage. To properly evaluate, it was essential for the team to perform research on Dr. Han’s novel 
nanoparticles compositions and related methods for surface modification that enable the 
upconverting luminescence to optimize the efficient excitation of 800 nm. One of the advantage 
of working on this sensitized tri-doped UCNP is a biocompatible activation and emission 
wavelengths that can be altered based on the molar composition while the particles brightness can 
be controlled through epitaxial growth and allotropic phase transfer. Both of these changes is a 
single crystal soft film coating applications as semiconductor and the element structure are bonded 
together in a different manner. Therefore, if we can better understand the tissue material properties 
and photodynamics, then we are one step closer to achieving deep tissue disease treatment via the 
combination of two inactive components, visible light and a photosensitizing drug.   
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If we can better understand the optimal conditions for safe, optical tissue penetration, the 
particles can be tuned to produce a desired emission wavelength from the desired activation 
wavelength, such as that necessary to photocatalyze PpIX to produce reactive oxygen species. It 
is therefore not only critical to understand the effects of the lasers on tissue but also the effects of 
nanoparticle energy transduction within the cell or extracellular space. This requires an extensive 
knowledge of system components and the alternatives available. Material science and engineering 
are key to identifying the necessary changes to increase the effectiveness of the Han lab’s approach 
to photodynamic therapy. 
4.2 Alternative Designs:  
Many aspects of the final design can be controlled during synthesis. 
Polymorphism is physical property that can be controlled during the synthesis and refers 
to the two atomic lattice crystal structures provides a matrix to bring these centers into optimal 
positions. Synthesizing the alpha phase particle is the first step in the 2- step thermolyisis method. 
The alpha-to-beta phase transition is achieved by cleaning, drying, and dispersing in solvents 
where it is heated to 300 C and cooled at a rate of 15 C per minute. The alpha particles occupy a 
(BCC) cubic space lattice while the beta particles occupy a hexagonal (HCP) structure. Last year’s 
MQP team was able to show that using an alternative CaF2 ceramic host lattice in the synthesis of 
alpha phase nanoparticles increases their efficiency while a NaYF4 host lattice is most suitable for 
efficient beta particles. There are a variety of alternative dielectric-ceramic host lattices available 
when considering research into nanoparticle synthesis including, LaF3, YF3, Y2O3, or LaPO4.  
An ideal host lattice for this application must be optically transparent, reduce lattice surface 
defects, and be dielectric. The beta particle has been shown to be the brighter. However, the beta 
26 
 
 
particles require more materials, result in a lower yield of end product, and have a tendency to 
agglomerate during synthesis, resulting in undesirable particle size.   
One of the most flexible components of our nanoparticle is the molar concentration of 
dopant precursors. Because the HCP crystal lattice is a close-packed structure, there is no room 
for dopant molecules to occupy free space between the atoms so they instead occupy a variety of 
defects in the dielectric crystal lattice. Changing the concentration of dopant precursors lies at the 
heart of UCNP technology. Altering the concentration allows for the UCNPs photodynamic 
properties such as activation and emission wavelength, transduction efficiency, and also degree of 
difficulty in synthesis. For example, our particles utilize a core that is theoretically occupied by 
100% dopant molecules, this characteristic makes our particles difficult to synthesize but the core 
is able to produce brighter blue light emission.  
4.3 Final Design: 
 Given the variety of technical parameters involved with our nano-scale transduction 
mechanism, we identified each parameter and how it functions with respect to our sponsors 
objectives. Last year’s MQP team was able to produce positive results that demonstrate substantial 
singlet oxygen production under 1.2cm of pork tissue using UCNPs as transducer. The goal of 
their project predominantly focused on to enhance the light penetration and reach deeper tissue 
using the UCNPs as transducer that convert 980nm NIR to red visible light and activate ALA to 
produce singlet oxygen. Adding a second epitaxial shell to the nanoparticles has been shown to 
increase luminescence intensity by decreasing emission deactivations caused by crystal surface 
structures limit the light penetration through tissues makes this treatment ineffective in the 
treatment of bulky tumors. The drawback of this approach is the increase in size associated with 
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the added epitaxial shell that cause light hypersensitivity and inefficiency in the management of 
metastatic tumors.  
In addition, nanoparticles with diameters less than 50 nm have been shown to be most 
effective at entering the cell. Since the cellular uptake mechanisms are not well understood, we 
intended to compare the cell viability of the core-shell-shell particle with the core-shell particle 
and then, determine whether the negative effects of size would outweigh the positive effects of 
increased luminescence intensity on cell death. The increase in particle size also provides a larger, 
and more uniform surface area which could potentially serve to increase the total number of 
binding sights for ALA which induce PpIX accumulation.   
A variety of ALA uptake mechanisms have been under research to help enhance the 
effectiveness of PDT. The best strategy was for coating UCNPs with polymer shells for their 
protection, functionalization, conjugation, and for biocompatibility (Beyazit et al.) Thus, if the 
final diameter of the ALA-Hyd-PAA-UCNP is less than 100nm, it could be injected directly into 
tumor tissue where ALA can be released within the cell or possibly in the extracellular space taken 
by the cell through a variety of transport mechanisms. There are multiple approaches to sub-dermal 
or deep tissue photodynamic therapy. As Malgorzata et al. suggested that ALA pharmacokinetics 
is essential to design most effective ALA-PDT to enhance its permeability through the lipid 
networks in the stratum corneum. One of the techniques being implemented in Dr. Hans’s lab was 
the applications of lanthanide based up-conversion nanoparticles as photo-excitable delivery 
vehicles, with the FDA approved pro-drug ALA strategically conjugated to the surface. 
Last year’s MQP group used a core@shell (@ is a popular way to say a core shell 
nanostructure, and we speak @ as "at". A@B usually means that A is the core and B the shell) 
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particle α-NaYF4:Yb80%Yb,2%Er@CaF2 which emits red light at 980 excitation. They were able 
to show that increasing the Yt concentration of particles results in an increase in red emission while 
an increase in Nd will result in an increase in blue emission while also tailoring the excitation 
wavelength to 800nm. So, we used core@shell@shell UCNP in our project: NaYbF
4
:0.5%Tm 
@NaYF
4
:30%Nd @NaYF
 4 
as shown in figure 2. Our particles were synthesized in organic 
solvents at 300 oC using a modified two step thermolysis method which leaves hydrophobic 
ligands present on the particle surface. Tm nanoparticles were shown to produce UV or blue light 
emissions while Er particles have been shown to produce green or red particles. The excitement 
associated with recent nanoparticle research has contributed greatly to the variety of dopant 
combinations and the effects they have on and particle efficiency and resonant energy transfer or 
the ability to fine tune the activation or emission wavelengths of UCNPs for PDT. 
 
Figure 2: Upconversion Nanoparticle Diagram 
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We began our experiments by chemically exchanging the toxic oleic acids ligands with an 
optically transparent and biologically inert PAA coating. We did this by first thoroughly rinsing 
the particles, followed by an NOBF4 treatment, and then mixing in excess PAA solutions. Then 
the particle were conjugated to hydrazine to make our UCNP hydrophilic. Lastly, we were able to 
complete ALA conjugation as shown in figure 3.   
 
Figure 3: Left side: The process of Conjugation 5-Aminolevulinic acid on NaYbF
4
:0.5%Tm 
@NaYF
4
:30%Nd @NaYF
 4, On right side: Conjugated UCNP 
Lanthanide doped upconversion nanoparticles have the potential to trigger subcutaneous 
tumor cell death. ALA is conjugated to a PAA coated UCNP and delivered to HELA cells in vitro. 
A pH sensitive hydrazine linkage allows for ALA to be released upon entry into the cell. ALA it is 
then converted to PpIX by the mitochondria and released into the cytosol. PpIX is a photosensitive 
molecule capable of catalyzing free radicals from molecular oxygen within the cell when exposed 
to UV light. Since UV light does not travel well through tissue, upconversion nanoparticles are 
used to convert, tissue-penetrating-NIR-light to PpIX-activating-UV-light. The overexpression of 
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PpIX normally found in cancer cells, combined with the ALA induced PpIX stimulation, creates a 
localized sensitivity to the upconversion UV emission, produce singlet oxygen which results in 
localized tissue death upon irradiation as shown in the figure 4.  
 
Figure 4: Schematic of final design components and its work mechanism 
The photosensitizer that our UCNP transduction mechanism utilizes is the naturally 
occurring PpIX molecule which has a range of activation wavelengths between 470nm-640nm 
which falls towards the UV end of the visible spectrum. If we can determine at which wavelength 
PpIX excitation produces the most effective MTT results, we can then adjust our dopant 
concentration in order to produce the optimal emission wavelength upon excitation. Our core shell-
shell particle utilizes an emission wavelength of 470 nm which is a blue colored visible light. There 
are a variety of photosensitizer molecules available when designing a UCNP for PDT mechanism. 
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Many approaches bind or conjugate the photosensitizer directly to the nanoparticle which can then 
be delivered and activated as a single unit. Organic dyes have been shown to be effective at PDT 
delivery but also demonstrate toxic effects and increase particle size. 
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Chapter 5: Design Verification 
 In order to address if our UCNP have consistent size, well conjugated, enhanced heating 
effects and MTT assay, we looked into some experiments.  
5.1 Transmission Electron Microscopy (TEM) 
It is necessary to keep the size of UCNP consistent and within the range of 30 – 65nm, so 
UCNP’s can be up-taken by cells easily. Transmission electron microscopy (TEM) technique was 
used to image UCNPs to visualize the consistency of the size of the UCNP in which a beam of 
electrons is transmitted through an ultra-thin specimen, and interact with the specimen when it 
passes through. This technique was used three times, first to visualize size of core 
NaYbF4:0.5%Tm, secondly the size of core and shell NaYbF4:0.5%Tm @NaYF4:30%Nd and 
lastly for core/shell/shell NaYbF4:0.5%Tm @NaYF4:30%Nd @NaYF4 as shown in figure 5 a, b, 
& c.  
 
Figure 5: TEM images of core@shell@shell particle (a), Core: NaYbF4: 0.5%Tm (b), Core@shell: 
NaYbF4:0.5%Tm@NaYF4:30%Nd (c), Core@shell@shell: NaYbF4:0.5%Tm@NaYF4:30%Nd@NaYF4 to 
see the consistency of size at 100nm scale bar.  
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The TEM results showed that our final core@shell@shell nanoparticles possess a 
uniform size of ~50nm with a narrow size distribution, as shown in Figure c. This size of 
UCNP is appropriate for tumor accumulation. 
5.2 Fluorometer 
 The fluorometer was used to compare the emission spectra of the uncoated UCNP’s 
to the PAA-UCNP’s in hexane to see the effect of PAA to the UCNPs. The measurements 
provided the following data using the background total intensity as measure of signal to 
noise ratio in 0.85W/cm2 power density and that influenced by factors like the quality of 
the optics and scattered light in the system. We discovered that the PAA-UCNP’s 
maintained a maximum emission peak at 475nm (Soret Band) with 3 smaller emission 
peaks (Q Bands) at 449nm, 360nm and also 512nm both in water and Hexane as shown in 
figure 6. It proves that our UCNP emit 475nm blue light when shine an 800nm near infrared 
light and the role of NIR-to-blue visible light transducer for endogenous PpIX.  
 
Figure 6: Emission Spectra of PAA-UCNPs in Hexane and UCNPs in Hexane both in 10mg/mL  
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5.3 Methylthiazol Tetrazolium (MTT) Assay 
 Methylthiazol Tetrazolium (MTT) assay was performed to verify the toxicity of 
ALA-UCNPs to HELA cells, which mean that UCNP minimally toxicto healthy cells. 
HELA human cervical cancer line was chosen to conduct this experiment and Antibiotic-
free DMEM+10% FBS was used to maintained the cultures by avoiding bacteria. All 
assays were performed under sterilized hood and incubated at 37 oC and 5% Carbon 
Dioxide (CO2). All cells count were determined by using disposable hemocytometer.  
1x104 HELA Cells were plated in a 96-well microtiter plate and incubated for 37 
oC with 5% carbon dioxide (CO2). The experiment was setup for three controls, 1) Cells 
with 5µl ALA-UCNP, 2) Cells with 10µl ALA-UCNP, 3) Just cells. Cells in first four 
columns of plate were exposed to 100µg/mL of ALA-UCNPs, cells in next four column 
were exposed to 200µg/mL of ALA-UCNPs and cell in last four columns were not exposed 
to UCNPs (growth control). After four hours two wells of each group was irradiated with 
CW 800nm laser diode at 0.7W/cm2 for 15 minutes then incubated the plate for another 24 
hours. Cells were washed with PBS and then were labeled with 12mM solution of MTT in 
PBS for 4 hours. Lastly the media was aspirated and replaced with 50µl DMSO and plate 
was read at 540nm absorption to determine the formazan absorption.  
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Figure 7: Cell Proliferation Assay (MTT): Where HELA cells were exposed to 100µg/mL ALA-
UCNPs, 200µg.mL ALA-UCNPs and nothing (growth control) and irradiated with CW 800nm 
light at 0.7W/cm2power density. 
 Our results showed that irradiation without adding UCNP to cells or UCNPs 
without irradiation are non-toxic to cells. On the other hand, when UCNPs were exposed 
to cells and irradiate the cells then UCNPs became toxic to cells. The results showed 
200µg/mL ALA-UCNP killed almost 54% cells after 15 minute irradiation, 100µg/mL 
ALA-UCNP killed almost 22% cells after 15 minute irradiation while other controls had 
minimal cytotoxicity. The statistical analysis showed that there is significant difference 
between 200µg/mL ALA-UCNP without irradiation and 200µg/mL with irradiation. This 
difference proved that UCNP without irradiation are minimal toxic to HELA cells.  
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5.4 Heating Effect Experiment 
 Since our project focused on improving the current UCNP design by changing the 
excitation wavelength we set up experiment to compare the 800nm and 980nm lasers and 
determined which is more effective for PDT based on heating effects. Our experiment was 
performed on 1.5cm thick pork tissue that was stored in a 0 oC refrigerator and allowed to 
sit out in room temperature for half an hour. Prior to testing a microscope was used to set 
this experiment. The microscope was modified by taking out one lens and by fixing the 
laser in lens place and aligned in a way to pass through the pork tissue as shown in figure 
8. On the side of the microscope the IR temperature sensor was adjusted which can measure 
temperature of the pork repeatedly with +/- 0.2C precision and accuracy.  
 
Figure 8: Microscope set up to test heating effect of 800nm & 980nm laser 
Modifying allowed us to precisely control light exposure and reduce atmospheric 
attenuations for repeatable measurement. When pork tissue was completely thawed it was 
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placed on the microscope glass plate. After making sure that everything is fixed and placed 
correctly multiple pork tissue were irradiated with both 800nm and 980nm on three 
different power densities 700mW/cm2, 1000mW/cm2, and 1300mW/cm2 respectively for 
5 minutes and temperature was record via the IR temperature sensor. 
 
Figure 9: Heating effect data of both 800nm and 980nm laser at three different power densities 
700mW/cm2, 1000mW/cm2, and 1300mW/cm2 showed the average temperature increase of the 
pork tissue based on all measurements taken during each time period.  
The 700mW/cm2 power density is the FDA approved power density because it 
shows minimal heating effects. Our data shows that the 980nm laser has a significantly 
higher heating effect on pork tissue than the 800nm laser on all the power densities as 
shown in figure 9. As the power density of the lasers were increased, the gap between the 
temperatures differences also increased which illustrates higher power density also 
increase the heating effects.  
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Chapter 6: Discussion  
Like other cancer treatments such as chemotherapy radiotherapy and surgery there 
is one treatment called Photodynamic therapy (PDT) on which our project was 
concentrated on. Upconversion nanoparticles (UCNP) are currently being used with PDT 
for cancer treatments and have shown promising results (Mahmoud El-Rifai, 2014). It is 
proven that UCNP with 980nm laser can be used in PDT for cancer treatment from previous 
MQP; however, there were few limitations with 980nm laser such as higher heating effects 
in the tissue and less tissue penetration (Mahmoud El-Rifai, 2014). The project was mainly 
focused on showing that NaYbF4:0.5%Tm@NaYF4:30%Nd@NaYF4 particle has less 
heating effects, enhanced MTT essay by increasing blue light emission through 
photodynamic therapy use with our UNCPs, which activates 
NaYbF4:0.5%Tm@NaYF4:30%Nd@NaYF4 the photosensitizer drug 5-Aminolevulinic 
Acid (ALA). From previous MQP we added another shell of neodymium this shell was 
added to beta phase because it cause higher energy transfer and emits brighter blue light 
which has shorter wavelength and higher frequency. The team conducted variety of 
experimetns to confirm that UNCPs has low toxicity when exposed to cells and the blue 
emission has higher intensity than red emission by using 
NaYbF4:0.5%Tm@NaYF4:30%Nd@NaYF4 and the ALA-UCNPs conjugation has 
therapeutic potential.  
 The team conducted experiments to evaluate the cell viability, heating effects, blue 
emission light and size with ALA-UCNPs conjugated particles to use core@shell@shell 
UCNPs as an activator and drug carrier for ALA these were compared to previous MQP. 
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After discovering that our UCNPs has best blue emission, which synthesized by team as 
discussed in appendix (I,II,III,IV) ALA-conjugated 
NaYbF4:0.5%Tm@NaYF4:30%Nd@NaYF4. ALA-UCNPs were expected to be 
phagozytized by the cells during MTT assay. While hydrazine-UCNP in endosome gets 
activated by NIR light which causes PpIX to produce singlet oxygen (1O2) and eventually 
kills cancers cells. Lastly, we designed a closed experiment where no air can pass through 
and we can set it on a constant temperature because our temperature measurement utilizes 
an IR laser we have to make sure that there was no possibility of measurement interference 
from NIR excitation laser. Once the team had established optimal blue emission PDT effect 
of UCNPs heating effects of laser was desired. The team conducted a test on pork tissue to 
verify the heating effects as shown in figure 8. This test was conducted to prove that heating 
effects of 800nm is less than heating effects of 980nm which shows that there will be less 
damaging and burning of skin will be caused.   
Blue emission is very important because in PDT photosensitizer drug is activated 
by blue emission the team used ALA as a photosensitizer drug. Brighter blue emission light 
is important for PDT because it will activate the UNCPs which will induce ALA release 
and ALA will induce PpIX accumulations.  
The team wanted to check the size of the UCNPs which was ~50nm as shown in 
the figure 5c from transmission electron microscope (TEM) the size requirement fits the 
average range size which can be uptaken by cancer cells easily. We decreased the 
concentration of Yb3+ because it is shown that 80% of Yb3+ has higher heating effects which 
decreased the heating effects. To get brighter blue emission we added another shell of 
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neodymium which is shown in figure 2. After the ALA conjugation, UCNPs size was 65nm 
which is still in acceptable range because it can still be used in human and tumors cells still 
can uptake it, as TEM showed that particles formed a uniform pattern and ALA-UCNPs 
distribution in water.  
One of the important experiment team conducted was Methylthiazol Tetrazolium 
(MTT) Assay for different reasons firstly to check the toxicity of UCNPs (cell viability) 
and secondly to check the photosensitizer drug ALA to evaluate the cell for which HELA 
cells were used. In figure 7 cell viability is shown where ALA-UCNPs exposure to cells 
and with 15 min irradiation shows 54% viability, UCNPs were exposed to cells 4 hours 
before the test was conducted under CW 800nm 0.7W/cm2 excitation, it shows that UCNPs 
are non-toxic to cells without irradiation which shows 800nm UCNPs has excellent cell 
viability. 
6.1 Economics 
Photodynamic therapy treatment using UCNP on larger perspective, cancer 
treatment is one of expensive treatment in medical field which cost up to $100,000 for a 
year of treatment (Levy, 2013). Despite the high cost of this treatment still does not show 
high efficient in most of cancer cases. After the research on UCNP with 800nm laser, we 
hypothesize that PDT with UCNP has promising and less expensive treatment than existing 
treatments because the material for UCNPs and ALA are not expensive due to the tumor 
targeted nature of ALA.  
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6.2 Societal Influence  
Whenever a treatment is in the process of getting approved not only its benefits are 
seen but also its side effects are considered. After conducting the research team looked if 
it has any effects to environment. One of the important aspect is disposal of from 
manufacturing the material and as well as therapy itself. Research shows there is no harm 
to environment plants or animals while using Yb3+ because it water-soluble but can have 
mild-toxicity to water animals which is why monitoring the disposal process is important 
but it does not require any permit or license (Ytterbium Oxide, 2010).  
6.3 Political Ramification  
Cancer is well known diseases which has taken everybody’s attention globally. 
Medically many research are taking place to have a treatment which can be used globally. 
Since there are many factors which causes cancer such as tobacco, diet, genetic, chemical 
radiation etc.  
6.4 Ethical Concern  
The goal of team was to provide an alternative treatment for cancer by using PDT 
with AL-UCNPs which has potential to provide patients with minimal side effects as well 
as less expensive than existing treatments. Patients’ needs to inform how treatment works 
and limitation and risk of treatment are discussed such as minimum damaging of skin or 
tissues and not 100% of tumor cells will be killed. To insure the pain level and risks in vivo 
studies should be done before introducing to clinical trial. 
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6.5 Health and Safety 
One of the main goal of this project was to design a treatment which is safe for 
patient for which we considered toxicity and heating effects in vitro studies. As results 
shows this treatment will have less damaging of skin and kill more cancer cells. Safety is 
major goal for everyone which is why we accomplished a PDT with ALA-UCNP treatment 
which will kill only cancer cells with minimal damaging near healthy tissues with less 
damage to skin. This drug is designed to have minimal side effects to nearby healthy tissues 
and organs. The treatment should be noninvasive so the patient does not suffer a lot of pain.  
6.6 Manufacturability  
Our project is easily reproducible its one week process to synthesize the particle, 
after one week if it’s made correctly it can be used for cancer treatment. Since the project 
goal was not to look in to how it should be injected severe studies can be done on this 
matter. Since cancer is growing disease it should be affordable for people all over the world 
so everyone can take it benefits. Our UCNPs is better because it has great size, less heating 
effects and enhanced cell viability also it is less costly than existing treatments and has less 
side effects.   
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Chapter 7: Final Design and Validation  
 Cancer is a deadly disease, and which has various treatments but those treatments 
have limitations so an effective and safe treatment is needed. PDT shows promise for the 
treatment of cancer. The 980nm laser was already proven to be use for PDT to treat cancer 
but there were limitation such as less absorbance, and higher heating effects which can 
cause skin damaging and burning. Therefore, the team designed an 800nm upconversion 
nanoparticle conjugated with 5-aminolevulinic acid with photodynamic therapy to treat 
cancer with less heating effect and enhanced cell viability to make it more effective for 
cancer therapy.  
 
Figure 10: Schematic of final design mechanism A)Cellular Uptake, B)pH induced ALA release, 
C)ALA induced PpIX accumulation, D)NIR laser excitation, E)470nmUCNP emission, F)PpIX 
470nm absorption, G)PpIX photocatalyzes triplet oxygen, H)Singlet Oxygen causes cell death 
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In photodynamic therapy, cells uptake the UCNP, pH induced the UCNP and they 
release ALA, which induced PpIX accumulation. When NIR laser shined on UCNP, they 
emit visible light. PpIX absorbs this light and photocatalyze the singlet oxygen which 
eventually kills the cancer cells. The mechanism of final design is shown in figure 10. 
Several experiments were performed to validate the final design. 
7.1. Polymer coating and pro-drug conjugation. 
The team verified the translucent properties of ALA and PAA and determine how 
much they reduce the emission intensity of our particles and compare them with the 980 
nm particle to determine if there is any difference. In order to emit blue light and enhance 
the brightness of light the team used extra shell of neodymium around the UCNP which 
sense the 800nm light and helps to emit brighter blue light. Blue light have shorter 
wavelength and high frequency which help to produce more PPIX. The team successfully 
synthesis the core@shell@shell UCNPs and did the conjugation. Firstly, UCNPs were 
conjugated to NOBF4 to remove the original capping ligand on the hydrophobic UCNPs, 
because the ion NO+ can replace the rare earth ions and coordination ligands. In the next 
step, UCNP were synthesis by PAA for ligand exchange. Because it has excellent properties 
such as hydrophilicity, and non-toxicity it is more stable in water and as a capping agent 
PAA allowed for nanoparticles with bright emission in aqueous systems. Thirdly UCNPs 
were conjugated with hydrazine. The reason of using hydrazine is that it is positively 
charged, more stable in biological fluid and hydrophilic. Lastly, the particles were 
conjugated with ALA which help to induce PPIX accumulation.  
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7.2 Cell viability assay 
 The toxicity and effectiveness of the UCNPS with 800nm laser irradiation were 
verified by doing MTT Assay. The team verified in this experiment that the irradiation 
without UCNP or UCNP without irradiation are minimally toxic to cells. Also, two 
different concentrations 100µg/ml and 200µg/ml of ALA-UCNPS were compared when 
irradiated with 800nm laser for 15 minutes. The result of this experiments illustrate that 
UCNPs with irradiation are toxic to cells.   
7.3 Heating effects experiments 
Based on the fact that our cells are ~75% water and that water has an extinction 
coefficient that is 20X less at 800nm than 980nm (United States of America, Massachusetts 
Patent No. WO?2014?116631, 2014). To test the heating effects of the 800 and 980 nm 
lasers pork tissue which has a greater heating effect. Various power densities were used for 
this experiment in which FDA approved 700 mW/cm2 was included to test their 
effectiveness. The team determined that the 980 nm has a higher heating effect than 800 
nm, so skin burning and damaging can be lessened by using 800nm laser.  
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Chapter 8: Conclusion and Recommendations 
As we discussed in previous chapters, cancer is leading cause of death in U.S therefore, 
the current viable option to treat cancer is using PDT, which is an effective preventive 
treatment. Photodynamic therapy (PDT) with topical 5-aminolevulinic acid (ALA) is 
increasingly employed for cancer treatment and is combined with both light and a 
photosensitizing agent to produce reactive oxygen in cells. The aim our project focused on 
the ALA derivation to enhance its permeability through considering the alternative designs 
for biocompatibility and test various in vitro parameters that influence of tissue temperature 
on PpIX accumulation. The team hypothesize that surface modification are favorable for 
compound to reach the target site and improve the penetration depth based on material 
physical, chemical, or biological characteristics. Our major challenge was to alter the Yb3+ 
sensitized UCNPs since the peak absorption of Yb3+ ions excited at 980nm as a result, the 
cells and tissue withhold on this higher laser radiation and concurrently induce heat 
damage. 
Therefore, for design selection using the transmission electron microscopy (TEM) 
experiment showed that our final core shell/shell nanoparticles have uniform diameter, 
approximately 50nm in size. This modification confers the uniform particles size that 
enable to distribute the ALA-UCNPs in water that help to use for biological purpose. The 
UCNPs invention are preferably configured as Core@shell@shell: 
NaYbF4:0.5%Tm@NaYF4:30%Nd@NaYF4 with a biocompatible 800nm excitable 
property that employ Nd3+ as photosensitizer and Yb3+ as bridging ions that give a strong 
blue upconversion emissions without phot bleaching (Han, 2014).   
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Our team used similar experimental approach as the previous MQP team to test in vitro 
activity using biocompatible calcium fluoride (CaF2) shell UCNPs. Therefore using 
selected tested method, we were able to compare the uncoated UCNPs with PAA-UCNPs 
both within water and hexane. The coated PAA-UCNPs achieved a maximum emission 
peak at 475nm in water and 450nm in hexane. This indicates that two different conjugated 
sample were cheeked to see their usability in different environment through TEM and 
fluorometer experiment. Therefore, the results shows that for uniform particle size (50nm) 
under the 800nm NIR laser the coated PAA-UCNPs can emit enough blue brightness at 
nearly 5.58*107 A.U. Thus, the team proves the advantage of ALA derivatives over PAA-
UCNPs can mainly enhance the rate of their enzymatic conversion into photoactive 
compounds to reach the target site as well as improved skin penetration.  
Therefore, to verify the team’s design accomplishment we performed MTT assay if the 
ALA working effectively as cancer treatment through conducted acceptable particle dosage 
and see cell death by applying the 800nm wavelength laser exposure. MTT assay was 
performed to show that only the UCNPs without irradiation are not able to kill that much 
cells and our data show that almost 100% viability after 15minute of exposure for 800nm 
wavelength laser. However, 10µl ALA-UCNP showed about 54% cell viability on the same 
MTT assay for 15 minutes. Thus, this MTT assay proves theory that ALA conjugated 
UCNPs had the most cell died using the 800nm laser shine with 30% Nd3+. Thus, the ease 
of surface modification enable the team to use the right size of nanoparticle to create the 
cytotoxicity assay, which acceptable in physiological testing.  
Although substantial overheating may induces cell and tissue damage, some heating is 
needed to promote PpIX production from ALA in cells and in tissue. Also, because the 
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sensitizers absorb NIR photons and then transfer the energy to the activators, the 
temperature dependence of PpIX production may be used for improvement of PDT whether 
accumulation of PpIX can be selectively enhanced by minimizing the overheating effects. 
Therefore, since the team hypothesized that the 980nm laser, typically used to trigger the 
Yb3+ sensitized upconversion process, we wanted to substitute to 800nm to sensitized Nd3+ 
by building the core/shell/shell structure to ensure successive energy transfer between the 
mixtures of lanthanide elements. As preliminary in vivo test, the team performed on 1.5cm 
thick pork tissue to compare the heating effects between 980nm laser, which is strongly 
absorbed by water in biological tissue and could cause sever overheating effect whereas 
800nm laser results confirmed that local overheating effect is greatly minimized. We tested 
on the pork tissue both 800nm and 980nm on the three different power densities and thus, 
we can conclude that our observation promises Nd3+ →Yb3+ as bioprobes for both in vitro 
and in vivo imaging under 800nm irradiation.  
8.1 Recommendations 
The main problem with the current PDT treatment is limited penetration depth due 
to inefficient NIR wavelength to activate ALA and limited accumulation of PpIX in the 
underlying stroma that may damage of deeper layer or the PpIX fluorescence not able to 
observed deeper tissue. Unfortunately, this set of experiments did not include the testing 
for tissue penetration depth and oxygen availability test due to lack of experimental 
laboratory resources and time. However, we recommend the following further 
modifications and tests such as further modifications of ALA-PDT will improve the 
cellular permeability, because ALA is a polar molecule and has significant role in 
improving its cellular permeability, increased stability in physiologic pH, increase 
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selectivity. Second, investigate the necessity of Nd3+ by increasing the concentration under 
excitation of 800nm not only well away from peak absorption of water, but also essential 
to minimize overhear heating effects. Last, identify additional factors that affect ALA 
pharmacokinetics to design effective ALA-PDT through detail studies of molecular 
mechanics of cytotoxicity are required to implement in vivo test.
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APPENDIX  
Appendix 1: NOBF4 Ligand Exchange  
1. Get a fresh 20mL vial with a white cap  
2. Using the 1000µL pipette labeled ODE and a clean blue pipette tip, pipette 1mL of 
NaYbF4:0.5%Tm@NaYF4:30%Nd@NaYF4 nanoparticles into the empty vial. Do 
this quickly because the hexane likes to drip all over the place. 
3. Using the same pipette and more fresh tips, pipette 4 mL of hexane into the same 
20mL vial with 1mL nanoparticles.  
4. Using the same pipette and more fresh tips, pipette 5 mL of DMF into the same 
20mL vial with 1mL nanoparticles and 4 mL hexane. You will see that the DMF 
and hexane are immiscible. 
5. Find the 20mL white capped vial on top of the vacuum oven filled with stir bars 
with the words "NOBF4 Hexane" on them. Take a pair of forceps/tweezers and 
wash them in hexane over the organic solvents dump. Then, use the tweezers to 
transfer one stir bar from the "NOBF4 Hexane" vial to your vial with nanoparticles, 
hexane, and DMF. 
6. Place your vial with a stir bar, nanoparticles, hexane, and DMF under a fume hood 
on a magnetic stirrer (best to use the hood across from the vacuum oven. Use the 
magnetic stirrer which is small, blue, and from VWR, not the ones from Corning). 
Close the vial with the white cap and turn it up the maximum stir speed. Stabilize 
the stirring by moving the vial to the center of the stirrer. You should see the hexane 
and DMF forcibly mixing.  
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7. Get a disposable scoop under the hood, carefully open the vial with nanoparticles 
while it's stirring. With the NOBF4 in one hand and the scoop in the other while 
keeping everything under the hood, open the NOBF4 bottle. You might see the 
contents start smoking--that's okay.  
8. Now, scoop .2g of the NOBF4 and add it to the vial with the nanoparticles stirring. 
Since you can't measure the NOBF4 outside the hood, you have to guesstimate what 
.2g looks like. After the NOBF4 is added to the vial, immediately close both the 
vial and the NOBF4 bottle tightly. You should see the nanoparticle solution turn 
green and blue, maybe with some green gas on top.  
9. Let the reaction sit overnight! 
Appendix II: Exchange anionic ligands with PAA on UCNP 
1. Take the UCNPs+hexane+DMF+NOBF4 mixture that has been stirring overnight 
and stop the mixing and open it under the hood. Let the gas escape. Get a 50 mL 
conical tube. Using a magnet to keep the stir bar in, pour the contents of the vial 
into the conical tube.  
2. Find the isopropanol spray bottle. Wash the sides of the vial with around 5mL 
isopropanol and pour the isopropanol into the hexane/DMF/UCNPs/NOBF4 
mixture. When you now mix the "yesterday"+isopropanol, you should see it swirl 
and clarify. Wash the vial again with another 5mL for a total of 10mL isopropanol 
in the conical tube (a total 20 mL volume since the initial mixture was 10 mL) 
3. Close the conical tube and keep swirling it until you might see a small precipitate. 
Create a water balance for it and centrifuge it on the countertop centrifuge next to 
the vacuum oven at maximum (7000) speed for about 10 minutes.  
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4. Take the conical out. If the pellet looks white and homogeneous, you can do the 
next step. Otherwise, decant the supernatant, redissolve in 10mL DMF using the 
sonicator, and centrifuge again. 
5. Decant the supernatant and redissolve in 10mL DMF using the sonicator. 
6. Prepare a 10 mL 10mg/mL Poly (acrylic acid) (PAA)/DMF solution in a 50 or 100 
mL single-necked round bottom flask. Dissolve in the sonicator. 
7. Add a stir bar from the bottle labeled "PAA DMF" above the vacuum oven and 
place the flask in the oil via the clamp on top of the red hot plate in the fume hood 
behind the one where you stirred the UCNPS with NOBF4.  
8. Adjust the red hot plate settings to 80°C and 1000 rpm. 
9. Once the temperature is 80°C and it is stirring, use a 1000 µL pipette to 1 mL by 1 
mL pipette the 10 mL UCNP/DMF solution into the flask with stirring PAA/DMF 
solution at 80°C. Seal the flask and let it stir with heat overnight. 
Appendix III: Hydrazine Conjugation 
1. Take the PAA-UCNPs in DMF that have been mixing at 80°C overnight and stop 
the mixing and heat. Use a Kim wipe to wipe away the oil from the bottom of the 
flask as you take it out of the clamp and into a holder. Using a magnet to keep the 
stir bar in, decant the contents of the flask equally into 2 fresh 50mL conicals. 
2. Wash the insides of the flask with around 5mL hexane using the spray bottle. Swirl 
the flask around and decant again into 1 conical. Wash the flask with 5mL hexane 
again and decant into the same conical tube. The hexane and PAA-UCNPs in DMF 
should not mix.  
3. Wash the sides of the flask with around 5mL isopropanol using the spray bottle. 
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Swirl the flask around and decant again into the same conical. Swirls around the 
tube and you should see the two solvents mix (and sometimes get very turbid). 
Wash the flask with 5mL isopropanol again and decant into the same conical tube. 
Keep swirling the conical until you see a small precipitate. The volume of the tube 
should be 30mL (10 mL PAA-UCNPS/DMF, 10mL hexane, 10mL isopropanol). 
4. Repeat steps 2-3 for the other conical with the other 10mL of PAA-UCNPS in 
DMF. 
5. Balance your two conicals with isopropanol and ask Xiang for help to spin it at 
11,000 rpm for 30 minutes at 20°C in the big departmental centrifuge. He will teach 
you how to use it so you can do it by yourself in the future. Keep a timer for the 30 
minutes. 
6. Immediately after the centrifuge stops, take the tubes out and bring it to the dark 
room. Test and see using the pen laser whether the nanoparticles have collected in 
the pellet and there is not much in the supernatant. If there is still some nanoparticles 
in the supernatant, centrifuge again. Otherwise, continue. 
7. Decant the DMF/hexane/isopropanol into the organic solvents dump and flip over 
the tubes on towels, Let all the solvent trickle down the side and onto the towels.  
8. Afterwards, us a 1000µL micropipette to add 10mL of DI water to each tube. Close 
the tubes and sonicate until the pellet is dispersed in the water. The water 
might/should be much more turgid, and that is okay. Check it with the laser and 
you might/will see it significantly dimmer and grainier, but that is okay.  
9. Balance the tubes and centrifuge them at 11000 rpm for 30 mins. Again, afterwards, 
check with a laser and if it's done decant the supernatant. 
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10. Repeats steps 8-9 two more times, washing the PAA UCNPs in water. Finally, 
resolubilize in 5mL PBS. Of that 5mL sample, take 1 mL and save it in the very 
small black-topped glass vial. 
11. Afterwards, if when you shine the laser into the solution there still seems to be a 
granular look to the luminescence, centrifuge the two tubes in the counter top 
centrifuge at max speed for less than 10 seconds and check the supernatants. If you 
can still see a lot of luminescence but without the grains, save the supernatant and 
dispose of the pellet. If you see nothing, resolubilize the pellet and centrifuge for 
less amount of time/at slower speed. If you still see the granular pieces, repeat this 
again.  
12. Once you have decently-bright non-granular PAA UCNPs dissolved in 4mL PBS, 
transfer the solution to a clean white capped vial and add a fresh stir bar to it. Place 
it on one of the small VWR blue magnetic stirrers under a hood and turn it up to 
max speed. Stabilize the stirring by centering the vial. 
13. Find the EDC in the -20°C freezer and the sulfo-NHS in the low humidity cabinet. 
Weigh 50mg of EDC and 25 mg of sulfo-NHS on the same weigh paper on the 
analytical balance. Transfer the EDC and sulfo-NHS to the stirring PAA-
UCNPS/PBS solution by folding the paper and pouring it in to the vial and trying 
to remove anything that stuck to the paper. Let the PAA-UCNPs react with the EDC 
and sulfo-NHS for 2 hours. 
14. After 2 hours, take the contents of the vial and decant it into a clean 50mL conical 
(keep the stir bar in with a magnet). Save the vial with the stir bar and close it under 
the hood. Create a water balance for the conical you just filled and centrifuge the 
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tube for 30 mins at 11000 rpm at 20°C. Afterwards, immediately check the pellet 
and supernatant (you know what I mean), decant, and resolubilize in 5mL PBS 
using a sonicator.  
15. Transfer those 5mL PBS to the vial you were stirring the nanoparticles and 
EDC/sulfo-NHS in before and continue mixing on the same stirrer.  
16. Now comes the dangerous part :) Using an automatic propipetter (the one that has 
to plug in to the outlet) and a 5mL glass graduated pipette, add 5 mL hydrazine 
monohydrate to the vial of EDC/sulfo-NHS activated UCNPs in PBS. This 
hydrazine stuff is used in rocket fuel and is highly reactive. Wear gloves and keep 
everything under the hood. Try not to make it touch any plastic and close it tightly 
after you're done. You might notice that the contents of the vial will get a bit warm 
after you add the hydrazine, which is a good sign.  
17. Let it react overnight. 
Appendix IV: ALA-Coupling 
1. Take the UCNPs that have been mixing with hydrazine, EDC, and sulfo-NHS 
overnight and place them in the 4°C fridge (under the pH meter) for a second. 
Meanwhile, get a fresh 50mL conical and water balance. After 5 mins in the fridge, 
take the vial out and using a magnet to keep the stir bar in, decant the contents into 
the fresh conical. 
2. Make a water balance for the conical and centrifuge it 11,000 rpm, 30 min, 20°C. 
Immediately after the 30 mins, go and take the tube out and check to make sure the 
supernatant has no UCNPs in it with both the pen laser and the big laser (around .5 
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amps). If there is still some, centrifuge for another 20 mins. Otherwise, quickly 
decant the supernatant into the sink and wash down with the tap running.  
3. Resolubilize the Hyd-UCNPs in 5mL of DI water. 
4. Repeat steps #2-#3 two more times to make absolutely sure there is no free 
hydrazine on the UCNPs by washing it multiple times.  
5. After the last wash, find the bottle in my desk which says “methanol and acetic 
acid”. Pipette 5mL of that into the conical to resolubilize the UCNPs. If it’s not that 
soluble, that’s okay. Keep going with it and try to disperse it as best as you can.  
6. Repeat Step 2 and 5 once more to make sure there is no water and only methanol 
and acetic acid in the solution.  
7. After you have 5mL of Hyd-UCNPs in the “methanol and acetic acid” solution in 
a conical tube, transfer the contents of the tube into a fresh white-capped vial. Add 
a stir bar and place it on a medium-high speed stirrer.  
8. Find the bottle in my desk which says “ALA in methanol”. While the Hyd-UCNPs 
are stirring, add 4mL of this solution with a pipette to the vial. Afterwards, cover 
in aluminum foil and let it react overnight. 
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